-+ 0.00%
-+ 0.00%
-+ 0.00%

Actinogen's Xanamem fails to show statistically significant benefit on primary endpoint in Alzheimer's trial

PUBT·11/19/2026 12:45:31
Listen to the news
Actinogen's Xanamem fails to show statistically significant benefit on primary endpoint in Alzheimer's trial
  • Actinogen Medical reported Xanamem failed to significantly slow overall disease progression in its pivotal Alzheimer’s trial involving 247 patients over 36 weeks.
  • Participants older than 75 showed significantly higher disease stabilization rates, though disease slowing was not statistically significant.
  • The oral treatment maintained its favorable safety profile, with no serious adverse events attributed to the drug.
  • Management plans discussions with potential partners and the FDA to determine development options for older patients.
  • Topline results have been announced; further findings will be presented at a future scientific meeting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinogen Medical Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190745PRIMZONEFULLFEED9881218) on November 19, 2026, and is solely responsible for the information contained therein.